NCT04705766 KIDney Injury in Times of COVID-19 (KIDCOV)
| NCT ID | NCT04705766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | SARS-CoV Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-03-01 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2021-03-01 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.
Eligibility Criteria
Inclusion Criteria: * Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC * Age 18 years or older at enrollment * Race/ethnicity, sex, age, and phone and/or home/email address provided Exclusion Criteria: * Failure of a candidate participant to give written informed consent to comply with the study protocol * Hospitalization up to 4 weeks after SARS-CoV-2 test * History of kidney transplant * History of dialysis
Contact & Investigator
Minnie Sarwal, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT04705766 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying SARS-CoV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04705766 currently recruiting?
Yes, NCT04705766 is actively recruiting participants. Contact the research team at minnie.sarwal@ucsf.edu for enrollment information.
Where is the NCT04705766 trial being conducted?
This trial is being conducted at San Francisco, United States, Chicago, United States, Ann Arbor, United States.
Who is sponsoring the NCT04705766 clinical trial?
NCT04705766 is sponsored by University of California, San Francisco. The principal investigator is Minnie Sarwal, M.D., Ph.D. at University of California, San Francisco. The trial plans to enroll 2,000 participants.